Mixed Phase 2b Results for Alumis Lupus Drug; Company Eyes Phase 3 in Subgroup

Alumis’ Phase 2b LUMUS trial of envudeucitinib missed overall SLE endpoints but showed robust responses in IFNGS-high patients. Psoriasis NDA still set for Q4 2026.